ACT Biotech
717 Market Street
Suite 650
San Francisco
California
94103
United States
Tel: 415-230-3900
Fax: 415-230-3950
Website: http://www.actbiotech.com/
12 articles about ACT Biotech
-
Week in Review: Eddingpharm (Cayman) Inc. Buys ACT Biotech Assets For $95 Million
1/13/2014
-
Eddingpharm (Cayman) Inc. Acquired Global Rights To Oncology Assets, Including Telatinib, From ACT Biotech
1/8/2014
-
ACT Biotech Release: Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients
11/14/2011
-
ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at American Society of Clinical Oncology
6/2/2011
-
ACT Biotech to Present Significant Progress in Stomach Cancer Treatment at American Society of Clinical Oncology
5/19/2011
-
ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer
2/28/2011
-
ACT Biotech Release: Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity
1/20/2011
-
ACT Biotech Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer
10/11/2010
-
ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in Gastric Cancer
6/2/2010
-
ACT Biotech Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
1/22/2010
-
ACT Biotech Announces Treatment of First Gastric Cancer Patients with Telatinib in a Phase 2 Clinical Trial in the U.S. and Spain
7/30/2009
-
ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer HealthCare
5/7/2008